This report describes the frequency and characteristics of serious or life-threatening hypersensitivity reactions to the tuberculin skin test over an 11-year period through November 2000. There were 24 reports and no deaths, indicating that such reactions are rare (0.08 reported reactions per million doses of tuberculin).
threatening, requiring inpatient hospitalization or prolongation of existing hospitalization, or resulting in persistent or significant disability/incapacity. Fifteen reports were excluded: 11 were not considered to have been allergic events or to have been triggered by a hypotensive type of hypersensitivity (paresthesia, cellulitis, seizure, chest pain, viral infection, syncope, Guillain-Barré, and vaso-vagal reaction.), 2 had received another vaccine or skin test, and 2 had insufficient information. The remaining 9 patients had received only a tuberculin skin test. These were 8 women and 1 man, and the median age was 35.8 years (range, 24-53 years). Each had experienced an acute hypersensitivity reaction characterized by у1 of the following findings within 48 h of skin testing: angioedema, urticaria, or dyspnea. Table 1 describes the characteristics of the acute hypersensitivity reactions in these 9 patients. None of these patients had cardiovascular shock, and there were no deaths. However, 8 of 9 patients were hospitalized, and several were reported to have received treatments commensurate with anaphylaxis. During this 11-year period there were ∼300 million doses of Tubersol distributed within the United States, although the actual number of doses used is unknown.
Discussion. Even under the assumption of significant underreporting, the incidence of serious acute allergic reactions to tuberculin skin testing, specifically to Tubersol, is rare. We observed 24 serious reports in the United States over a time period in which 1300 million doses of tuberculin were distributed in the United States, for an apparent incidence rate of 0.08 per million doses, well below 1 per million doses.
In 1957, Cluff [3] reported a patient in whom immediate hypersensitivity to tuberculin developed after 7-8 tuberculin tests over 2 years. In 1977, Tarlo et al. [4] reported that immediate hypersensitivity responses to 10 tuberculin units of PPD occurred in (2.3%) of 3248 patients in an allergy clinic. The responses were all local reactions of the wheal and flare type, as observed with atopy. The mechanism for the immediate reactions was not elucidated by that study.
Immediate hypersensitivity reactions to tuberculin do occur, as shown by this review of our experience and by previous studies. Non-life-threatening reactions are not unusual; however, serious reactions as reported in this review are quite rare. Nevertheless, this review reinforces a precaution and recommendation that epinephrine should always be readily available in the event that a serious acute hypersensitivity reaction does occur after administration of a tuberculin skin test. 
